Several synthetic compounds have been developed to stimulate GH secretion; these include growth hormone-releasing peptides (GHRPs), growth hormone secretagogues (GSHs), and growth hormone (hGH) analogs. Studies suggest they may have synergistic effects when given to a test subject. Researchers speculate that increased fat metabolism, lean body mass, a regular sleep cycles, and healthy gut and heart function might be just a few. CJC-1295 is a 29-amino-acid synthetic peptide that mimics growth hormone (hGH) effects. Scientists have classified the synthetic pentapeptide Ipamorelin as a growth hormone secretagogue (GSH). As its name implies, Fragment 176-191 peptide is a short ‘fragment’ of the hGH hormone, consisting of just 15 amino acids. Research suggests this combination may stimulate the production of growth hormones by activating a specific area of the pituitary gland. Scientists hypothesize that this combination may effectively control and maintain healthy growth hormone levels.
Fragment 176-191, CJC-1295, and Ipamorelin Peptide Blend Research
Test subjects were recruited for this study [i]. The subjects were randomly assigned to either receive a saline placebo or the peptide. Before and after the peptide presentation, blood samples were taken from all models. Researchers suggested that the peptide group showed a 7.5-fold rise in growth hormone levels compared to the control group after the full trial. Researchers speculated these hormones seemed to rise steadily throughout the trial and to stay steady for at least 7 days after the presentation phase ended. Male subjects were observed in a separate study [ii]. The models were split into two groups, with 1/2 receiving a placebo and the other half receiving the peptide, much as in the prior trial.
Throughout the trial, the peptide group was given progressively higher quantities of the substance. Analyses of blood samples from these models suggested that those who had taken the peptides appeared to have much higher concentrations of growth hormones in their systems by as much as a factor of 10. Madalina Ionescu et al. write, “The marked improvement of trough GH levels by continuous GHRH stimulation suggests the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may help subjects with intact pituitary GH secretory capability.” [i]
Numerous investigations using growth hormone-deficient test animals have been performed since 2000. From what is known thus far, these peptides are thought to operate through one of two mechanisms:
- Possibility of inducing pituitary hormone secretion for growth.
- Possibility of affecting the hypothalamic arcuate nucleus. [iii]
Six growth hormone deficient subjects were recruited [iv] for eight months of exposure to varying amounts of growth hormone release boosting peptides in a clinical trial designed to assess the effects on young test subjects. Throughout the trial, models’ levels of growth hormone secretion were meticulously tracked. Following the study’s conclusion, researchers suggested that all subjects’ growth hormone levels seemed to have increased gradually and consistently, even when the peptide was no longer present. V Mericq et al. said the peptides were “well tolerated and may stimulate GH secretion.”
Fragment 176-191, CJC-1295, and Ipamorelin Peptide Blend and Lipolytic Action
The peptide’s potential lipolytic (fat-burning) activity was the subject of a clinical trial [v] in 2004.
300 test subjects were observed in this trial, and they were all presented with Fragment 176-191 peptides for 12 weeks. These models were randomly assigned to one of six groups, with some receiving a saline placebo and others being exposed to varying quantities of peptides. The findings suggest the group with the least amount of peptides looked to have lost as much as 2.8 kg in weight. These peptides may have also appeared to have improved these models’ lipid profiles and glucose tolerance. Over 12 weeks, the peptide appeared to have induced competitive weight reduction with attendant health properties, as suggested by the study team.
More study is needed to understand the mechanism of action of this peptide blend, and its full potential in research applications. Fragment 176-191, CJC-1295, and Ipamorelin Peptide Blend is restricted to usage in research and educational institutes. Licensed professionals may consider Core Peptides as a great resource for reputable peptides. This article’s information is meant only for educational purposes.
[i] Ionescu M, Frohman LA. Pulsatile growth hormone secretion (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
[ii] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
[iii] Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694.
[iv] Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60. https://pubmed.ncbi.nlm.nih.gov/9661608/
[v] News, Medical and Life Sciences, Obesity drug codenamed AOD 9604 highly successful in trials, 16 December 2004, https://www.news-medical.net/news/2004/12/16/6878.aspx